Case report: Lyell leverages Werum PAS-X MES as a Service for clinical phase production

The US-based cell therapy biotech Lyell Immunopharma has successfully taken Werum PAS-X MES as a Service into operation at their GMP production site in Bothell, WA to produce autologous T cell cancer therapies.